These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23116363)

  • 1. Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men.
    Liem-Moolenaar M; Peeters P; Kamerling IM; Hogg C; Holder G; Kleijn HJ; Spaans E; Udo De Haes J; de Kam ML; Franson KL; Cohen AF; van Gerven JM
    Br J Clin Pharmacol; 2013 Jun; 75(6):1455-67. PubMed ID: 23116363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects.
    Liem-Moolenaar M; Zoethout RW; de Boer P; Schmidt M; de Kam ML; Cohen AF; Franson KL; van Gerven JM
    J Psychopharmacol; 2010 Nov; 24(11):1681-7. PubMed ID: 19648218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects.
    Liem-Moolenaar M; Zoethout RW; de Boer P; Schmidt M; de Kam ML; Cohen AF; Franson KL; van Gerven JM
    J Psychopharmacol; 2010 Nov; 24(11):1671-9. PubMed ID: 20142308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol.
    Liem-Moolenaar M; Gray FA; de Visser SJ; Franson KL; Schoemaker RC; Schmitt JA; Cohen AF; van Gerven JM
    J Psychopharmacol; 2010 Jan; 24(1):73-82. PubMed ID: 18755817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central nervous system effects of haloperidol on THC in healthy male volunteers.
    Liem-Moolenaar M; te Beek ET; de Kam ML; Franson KL; Kahn RS; Hijman R; Touw D; van Gerven JM
    J Psychopharmacol; 2010 Nov; 24(11):1697-708. PubMed ID: 20142302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial.
    Schoemaker JH; Jansen WT; Schipper J; Szegedi A
    J Clin Psychopharmacol; 2014 Apr; 34(2):190-8. PubMed ID: 24525661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects.
    Astruc B; Tarral A; Dostert P; Mariotti F; Fabbri L; Imbimbo BP
    Br J Clin Pharmacol; 2005 Apr; 59(4):405-14. PubMed ID: 15801935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men.
    Liem-Moolenaar M; Rad M; Zamuner S; Cohen AF; Lemme F; Franson KL; van Gerven JM; Pich EM
    Br J Clin Pharmacol; 2011 Jun; 71(6):907-16. PubMed ID: 21223356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects.
    Liem-Moolenaar M; de Boer P; Timmers M; Schoemaker RC; van Hasselt JG; Schmidt S; van Gerven JM
    Br J Clin Pharmacol; 2011 Jun; 71(6):886-98. PubMed ID: 21306419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electroencephalographic and psychomotor effects of chlorpromazine and risperidone relative to placebo in normal healthy volunteers.
    Hughes AM; Lynch P; Rhodes J; Ervine CM; Yates RA
    Br J Clin Pharmacol; 1999 Sep; 48(3):323-30. PubMed ID: 10510142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
    J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of 50mg amisulpride on EEG, psychomotor and cognitive functions in healthy sleep-deprived subjects.
    Patat A; Rosenzweig P; Miget N; Allain H; Gandon JM
    Fundam Clin Pharmacol; 1999; 13(5):582-94. PubMed ID: 10520732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation.
    van Steveninck AL; van Berckel BN; Schoemaker RC; Breimer DD; van Gerven JM; Cohen AF
    J Psychopharmacol; 1999; 13(1):10-7. PubMed ID: 10221355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 1. EEG mapping, psychometric and tolerability findings.
    Saletu-Zyhlarz GM; Anderer P; Wolzt M; Semlitsch HV; Assandri A; Nessi P; Nannipieri F; Rosini S; Saletu B
    Neuropsychobiology; 2009; 59(2):100-9. PubMed ID: 19365150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative EEG, SPEM, and psychometric studies in schizophrenics before and during differential neuroleptic therapy.
    Saletu B; Küfferle B; Grünberger J; Anderer P
    Pharmacopsychiatry; 1986 Nov; 19(6):434-7. PubMed ID: 2879297
    [No Abstract]   [Full Text] [Related]  

  • 17. Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 2. EEG-tomography findings based on LORETA (low-resolution brain electromagnetic tomography).
    Saletu B; Anderer P; Wolzt M; Nosiska D; Assandri A; Noseda E; Nannipieri F; Saletu-Zyhlarz GM
    Neuropsychobiology; 2009; 59(2):110-22. PubMed ID: 19365151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised trial of the effect of the glycine reuptake inhibitor Org 25935 on cognitive performance in healthy male volunteers.
    Christmas D; Diaper A; Wilson S; Rich A; Phillips S; Udo de Haes J; Sjogren M; Nutt D
    Hum Psychopharmacol; 2014 Mar; 29(2):163-71. PubMed ID: 24424780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of intrapulmonary tetrahydrocannabinol administration in humans.
    Zuurman L; Roy C; Schoemaker RC; Hazekamp A; den Hartigh J; Bender JC; Verpoorte R; Pinquier JL; Cohen AF; van Gerven JM
    J Psychopharmacol; 2008 Sep; 22(7):707-16. PubMed ID: 18515447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of pharmaco-electroencephalography in early human-pharmacological evaluations of psychoactive drugs. First example: savoxepine.
    Herrmann WM; Schärer E; Delini-Stula A
    Pharmacopsychiatry; 1991 Nov; 24(6):196-205. PubMed ID: 1687485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.